All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431 #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference #HEPA globenewswire.com/news-release/2…

Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021 #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021 #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431 #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals Announces Death of Director, Thomas Adams #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company’s Strategic Medical Affairs in Asia #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial globenewswire.com/news-release/2… #HEPA

Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals Appoints Accomplished Life Sciences Industry Veteran, Dr. Launa J. Aspeslet, as Chief Operating Officer #HEPA globenewswire.com/news-release/2…

Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati #HEPA globenewswire.com/news-release/2…

We are closing the week with Hepion Pharmaceuticals at the Nasdaq Exchange Closing Bell. 🛎 $HEPA is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. #NasdaqListed